• Search
  • Helpdesk
  • Sales contact

Tackling the specificities of NASH/MASH clinical trials

Last updated: May 7, 2025

Integrating PROs into studies on MASH, also known as NASH, is crucial. 
MASH is a debilitating chronic illness that significantly impairs patients’ quality of life, affecting their daily routines, work, and mobility.

  • Patient-centric appraisals are needed in the quest for treatments
  • Integrating PROs in MASH studies expands insights beyond MASH metrics, and helps understand MASH patients’ concerns


At Kayentis, we have the full capability to run your MASH studies successfully:

  • We have extensive experience in MASH and hepatic disorders research
  • We offer an enhanced patient-centric eCOA data entry
  • We are a key partner to biotech and big pharma companies
 
Download the case study 👇
Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

PCMG 2026

JUNE 15-17 2026 • Berlin, Germany
Meet our colleagues Chris BARDEN and Andrea MURISON at PCMG.  Schedule a meeting

6th Annual Clinical Trial Innovation Summit

24 JUNE 2026 • BASEL, CH

DPHARM 2026

SEPT 15-16 2026 • Boston, MA, USA
Booth #306